944401-75-6

Basic information

• Product Name: 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine
• Synonyms: 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine;3-Fluoro-2-aminopyridine-5-boronic acid pinacol ester;2-PyridinaMine, 3-fluoro-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;6-Amino-5-fluoropyridine-3-boronic acid pinacol ester;3-Fluoro-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-ylamine
• CAS NO: 944401-75-6
• Molecular Formula: C₁₁H₁₆BFN₂O₂
• Molecular Weight: 238.068
• Mol File: 944401-75-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 335℃
• Flash Point: 157℃
• Appearance: /
• Density: 1.15
• Storage Temp.: 2-8°C
• PKA: 4.08±0.50(Predicted)
• CAS DataBase Reference: 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine(944401-75-6)
• EPA Substance Registry System: 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine(944401-75-6)

Safety Data

• Hazardous Substances Data: 944401-75-6(Hazardous Substances Data)

Usage

General Description

3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine is a complex organic compound that belongs to the class of compounds known as organoboron compounds. It represents a type of organofluorine compounds, which contain a fluorine atom attached to an organic group. The compound's structure contains a pyridine ring, which is a six-membered ring consisting of five carbon atoms and a nitrogen atom. A tetramethyl-1,3,2-dioxaborolan-2-yl moiety, an organoboron group, is attached to this pyridine ring. This chemical is used in various forms of chemical synthesis, often leveraging the unique properties of the attached boron and fluorine atoms for specific chemical reactions.

InChI:InChI=1S/C11H16BFN2O2/c1-10(2)11(3,4)17-12(16-10)7-5-8(13)9(14)15-6-7/h5-6H,1-4H3,(H2,14,15)

Upstream product

• 21717-95-3 3-fluoropyridin-2-amine 
• 73183-34-3 bis(pinacol)diborane 
• 748812-37-5 5-bromo-3-fluoro-pyridin-2-ylamine 

Downstream Products

• 1610610-94-0 3-(6-amino-5-fluoropyridin-3-yl)-N-(4-cyanophenyl)-N-methylpyrazolo[1,5-a]pyridine-5-carboxamide 

Relevant articles and documents

Small molecule compound

The invention provides a small molecular compound, The small molecular compound is characterized by having a structure as shown in the following molecular general formula, wherein X1 and X2 are selected from carbon or nitrogen, G1 is a carbon ring or a heterocyclic ring with aromaticity, any one or more hydrogen atoms on the G1 ring are substituted by R1, wherein R1 is selected from nitrogen-containing groups. The small molecule compound can be used as an efficient and specific JAK kinase inhibitor, especially a Tyk2 inhibitor, and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor, or a Tyk2/JAK1 dual inhibitor or a Tyk2/Jak2 dual inhibitor.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c] quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H- imidazo[4,5-c] quinofinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c] quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H- imidazo[4,5-c] quinolinone derivatives; and a process for the preparation of the novel 1H- imidazo[4,5-c] quinolinone derivatives.